Patients with Osteoporosis: Children of a Lesser God

Overview

Journal RMD Open

Publisher BMJ Publishing Group

Specialty Rheumatology

Date 2023 Feb 9

PMID 36759006

Authors

Giovanni Adami

Elena Tsourdi

Maurizio Rossini

Thomas Funck-Brentano

Roland Chapurlat

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is a common non-communicable disease with enormous societal costs. Antiosteoporosis medications have been proven efficacious in reducing the refracture rate and mortality; moreover, we have now convincing evidence about the cost-effectiveness of antiosteoporotic medications. However, albeit preventable and treatable, osteoporosis has been somehow neglected by health authorities. Drugs approval has been unnecessarily lengthy, especially when compared with other non-communicable diseases. Herein, we discuss the issue of procrastinating drug approval in osteoporosis and future implications.

Citing Articles

The role of Clec11a in bone construction and remodeling.

Xu K, Huang R, Wen R, Yang Y, Cheng Y, Chang B Front Endocrinol (Lausanne). 2024; 15:1429567.

PMID: 39188913 PMC: 11345164. DOI: 10.3389/fendo.2024.1429567.

References

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

Adami G, Jaleel A, Curtis J, Delzell E, Chen R, Yun H . Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart. J Bone Miner Res. 2019; 35(3):478-487. PMC: 7401723. DOI: 10.1002/jbmr.3915. View

Adami G, Saag K . Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int. 2019; 30(6):1145-1156. DOI: 10.1007/s00198-019-04906-x. View

Coassy A, Svedbom A, Locrelle H, Chapurlat R, Cortet B, Fardellone P . Costs of patient management over 18 months following a hip, clinical vertebral, distal forearm, or proximal humerus fragility fracture in France-results from the ICUROS study. Osteoporos Int. 2021; 33(3):625-635. DOI: 10.1007/s00198-021-06189-7. View

Bibbins-Domingo K . Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016; 164(12):836-45. DOI: 10.7326/M16-0577. View

Hsu Y, Li C, Liang F, Peng Z, Chang Y, Hsu J . Reduced All-Cause Mortality With Bisphosphonates Among Post-Fracture Osteoporosis Patients: A Nationwide Study and Systematic Review. Clin Pharmacol Ther. 2022; 112(3):711-719. DOI: 10.1002/cpt.2645. View

Papapoulos S, Quandt S, Liberman U, Hochberg M, Thompson D . Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int. 2004; 16(5):468-74. DOI: 10.1007/s00198-004-1725-z. View

Legrand M, Chapurlat R . Imminent fracture risk. Joint Bone Spine. 2020; 88(3):105105. DOI: 10.1016/j.jbspin.2020.105105. View

McMurray J, Solomon S, Inzucchi S, Kober L, Kosiborod M, Martinez F . Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381(21):1995-2008. DOI: 10.1056/NEJMoa1911303. View

10.

Silverman S, Curtis J, Saag K, Flahive J, Adachi J, Anderson F . International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int. 2014; 26(1):419-20. PMC: 4873770. DOI: 10.1007/s00198-014-2883-2. View

11.

Lyles K, Colon-Emeric C, Magaziner J, Adachi J, Pieper C, Mautalen C . Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357(18):1799-809. PMC: 2324066. DOI: 10.1056/NEJMoa074941. View

12.

Ray K, Wright R, Kallend D, Koenig W, Leiter L, Raal F . Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020; 382(16):1507-1519. DOI: 10.1056/NEJMoa1912387. View

13.

Adami S, Bertoldo F, Gatti D, Minisola G, Rossini M, Sinigaglia L . Treatment thresholds for osteoporosis and reimbursability criteria: perspectives associated with fracture risk-assessment tools. Calcif Tissue Int. 2013; 93(3):195-200. DOI: 10.1007/s00223-013-9748-0. View

14.

Tsourdi E, Rachner T, Rauner M, Hamann C, Hofbauer L . Denosumab for bone diseases: translating bone biology into targeted therapy. Eur J Endocrinol. 2011; 165(6):833-40. DOI: 10.1530/EJE-11-0454. View

15.

Kiebzak G, Beinart G, Perser K, Ambrose C, Siff S, Heggeness M . Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002; 162(19):2217-22. DOI: 10.1001/archinte.162.19.2217. View

16.

Sabatine M, Giugliano R, Wiviott S, Raal F, Blom D, Robinson J . Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1500-9. DOI: 10.1056/NEJMoa1500858. View

17.

Cosman F, Crittenden D, Adachi J, Binkley N, Czerwinski E, Ferrari S . Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016; 375(16):1532-1543. DOI: 10.1056/NEJMoa1607948. View

18.

Roux C, Thomas T, Paccou J, Bizouard G, Crochard A, Toth E . Refracture and mortality following hospitalization for severe osteoporotic fractures: The Fractos Study. JBMR Plus. 2021; 5(7):e10507. PMC: 8260818. DOI: 10.1002/jbm4.10507. View

19.

Vranken L, de Bruin I, Driessen A, Geusens P, Eisman J, Center J . Decreased Mortality and Subsequent Fracture Risk in Patients With a Major and Hip Fracture After the Introduction of a Fracture Liaison Service: A 3-Year Follow-Up Survey. J Bone Miner Res. 2022; 37(10):2025-2032. PMC: 9826296. DOI: 10.1002/jbmr.4674. View

20.

Martin J, Viprey M, Castagne B, Merle B, Giroudon C, Chapurlat R . Interventions to improve osteoporosis care: a systematic review and meta-analysis. Osteoporos Int. 2020; 31(3):429-446. DOI: 10.1007/s00198-020-05308-0. View